China
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients
FDA has granted it clearance to proceed with TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as first-line treatment in patients with HER2-negative, CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal (G/GEJ) adenocarcinoma
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
Arctic Vision is a specialty ophthalmology company based in China that has the exclusive license for commercialization and development of XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which they refer to as ARCATUS, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries.
上海浦东新区：推动产业与资本对接 打造生物医药世界级产业集群
上证报中国证券网讯 上海市政府今日举办新闻发布会，介绍2023上海国际生物医药产业周的有关情况。上海市浦东新区副区长吴强在会上表示，浦东新区将通过更高水平的科技创新和资本要素融合，助力浦东打造生物医药世界级产业集群。主要举措包括：
Precision Neuroscience wins FDA breakthrough nod for BCI, buys factory in Texas
Precision Neuroscience announced today that its brain-computer interface (BCI) technology won FDA breakthrough device designation.
Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments
“ALSP has long been interested in helping to drive biopharma innovation emerging in Singapore,” said Alice Chen, Executive Vice President at ALSP and Automera board member.
Triastek Completes USD 20.4 Million Pre-C Funding Round to Accelerate Commercialization of 3D Printing Pharmaceutical Technology and Products
Triastek, Inc. ("Triastek") today announced the completion of a USD 20.4 million Pre-C financing round. This milestone marks a significant step in the advancement of Triastek's innovative solutions for drug development and manufacturing.
UK drug giant AstraZeneca to set up research base in Hong Kong, city’s finance chief Paul Chan reveals on Europe work trip
Leading global pharmaceutical firm AstraZeneca will set up a research and development centre in Hong Kong, the city’s finance minister has revealed while on a work trip in Europe.
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
The ADSs are expected to begin trading on the Nasdaq Global Market on September 29, 2023 under the ticker symbol “ANL”.
Wuhan YZY Biopharma – HK$176 Million IPO
Wuhan YZY Biopharma offered a total of 11,001,200 H shares, priced at $16 per H share.
